THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN. Belluscura […]
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN. Belluscura […]
https://www.belluscura.com/wp-content/uploads/2021/05/Untitled-design-39.png34566912syedalidigitalhttps://www.belluscura.com/wp-content/uploads/2020/09/Belluscura-Logo-cl-2.pngsyedalidigital2021-11-29 09:06:082021-11-29 09:08:57Reimbursement approval from U.S. Centers for Medicare & Medicaid Services (CMS)
Belluscura PLC (“Belluscura” or “Company”) Exercise of Warrants and Total Voting Rights LONDON, U.K. AND PLANO, TX, U.S. (29 November 2021). Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces that it has received notification from a warrant holder to exercise warrants over 179,537 shares in […]
https://www.belluscura.com/wp-content/uploads/2021/05/Untitled-design-39.png34566912syedalidigitalhttps://www.belluscura.com/wp-content/uploads/2020/09/Belluscura-Logo-cl-2.pngsyedalidigital2021-11-29 09:04:122021-11-29 09:07:45Exercise of Warrants and Total Voting Rights
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN. Belluscura […]
CEO to present with London Stock Exchange Head of Primary Markets at an event in Dallas, Texas Bob Rauker to discuss accessing alternative sources of capital and his experience of listing a Company on the Alternative Investment Market (AIM) LONDON, U.K. AND PLANO, TX, U.S. (1 November 2021). Belluscura plc (AIM: BELL), a […]
X-PLO₂R™ wins gold award at Medtrade East 2021 in Atlanta LONDON, U.K. AND PLANO, TX, U.S. (25 October 2021). Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces that its X-PLO₂R™ portable oxygen concentrator won the Providers’ Choice Gold, the highest accolade to be given at […]
https://www.belluscura.com/wp-content/uploads/2021/05/Untitled-design-39.png34566912syedalidigitalhttps://www.belluscura.com/wp-content/uploads/2020/09/Belluscura-Logo-cl-2.pngsyedalidigital2021-10-25 10:40:042021-10-25 10:51:30Product wins Top Award at US Trade Show
24 May 2021 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM, THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, NEW ZEALAND OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO DISTRIBUTE THIS ANNOUNCEMENT. This announcement is an advertisement and not an […]
https://www.belluscura.com/wp-content/uploads/2021/05/Untitled-design-39.png34566912Belluscurahttps://www.belluscura.com/wp-content/uploads/2020/09/Belluscura-Logo-cl-2.pngBelluscura2021-05-24 01:01:162021-05-24 01:01:16Belluscura plc (UK)…Confirmation of Issue Price for Placing on the AIM market of the London Stock Exchange
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.AcceptPrivacy Policy
Demand for, and delivery of, X-PLO2R™ portable oxygen concentrator exceeds expectations
/in Belluscura News /by syedalidigitalTHIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN. Belluscura […]
Reimbursement approval from U.S. Centers for Medicare & Medicaid Services (CMS)
/in Belluscura News, Investors /by syedalidigitalTHIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN. Belluscura […]
Exercise of Warrants and Total Voting Rights
/in Belluscura News, Investors /by syedalidigitalBelluscura PLC (“Belluscura” or “Company”) Exercise of Warrants and Total Voting Rights LONDON, U.K. AND PLANO, TX, U.S. (29 November 2021). Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces that it has received notification from a warrant holder to exercise warrants over 179,537 shares in […]
Demand for X-PLO2R™ portable oxygen concentrators significantly exceeds expectations
/in Belluscura News /by syedalidigitalTHIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN. Belluscura […]
The Pulse: Healthcare Innovation Breakfast
/in Belluscura News /by syedalidigitalCEO to present with London Stock Exchange Head of Primary Markets at an event in Dallas, Texas Bob Rauker to discuss accessing alternative sources of capital and his experience of listing a Company on the Alternative Investment Market (AIM) LONDON, U.K. AND PLANO, TX, U.S. (1 November 2021). Belluscura plc (AIM: BELL), a […]
Product wins Top Award at US Trade Show
/in Belluscura News /by syedalidigitalX-PLO₂R™ wins gold award at Medtrade East 2021 in Atlanta LONDON, U.K. AND PLANO, TX, U.S. (25 October 2021). Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces that its X-PLO₂R™ portable oxygen concentrator won the Providers’ Choice Gold, the highest accolade to be given at […]
Admission Document
/in Belluscura News /by BelluscuraClick the link below to view the document. FINAL ADMISSION DOCUMENT (24 MAY 2021)
Belluscura plc (UK)…Confirmation of Issue Price for Placing on the AIM market of the London Stock Exchange
/in Belluscura News /by Belluscura24 May 2021 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM, THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, NEW ZEALAND OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO DISTRIBUTE THIS ANNOUNCEMENT. This announcement is an advertisement and not an […]